SEC FORM 5 SEC Form 5
FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden
hours per response: 1.0
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Form 3 Holdings Reported.
X
Form 4 Transactions Reported.
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10
1. Name and Address of Reporting Person*
Altamont Pharmaceutical Holdings, LLC

(Last) (First) (Middle)
5960 BERKSHIRE LN
FLOOR 6

(Street)
DALLAS TX 75225

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Galera Therapeutics, Inc. [ GRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
12/31/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Amount (A) or (D) Price
Common Stock 01/11/2024 01/11/2024 S4 400,000 D $0.2256 4,880,000 I See fn.(1)
Common Stock 03/22/2024 03/22/2024 S4 20,000 D $0.23 4,860,000 I See fn.(1)
Common Stock 03/25/2024 03/25/2024 S4 780,000 D $0.2189 4,080,000 I See fn.(1)
Common Stock 03/26/2024 03/26/2024 S4 2,000,000 D $0.1965 2,080,000 I See fn.(1)
Common Stock 03/27/2024 03/27/2024 S4 306,924 D $0.1699 1,773,076 I See fn.(1)
Common Stock 03/28/2024 03/28/2024 S 693,076 D $0.1459 1,080,000 I See fn.(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
(A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Altamont Pharmaceutical Holdings, LLC

(Last) (First) (Middle)
5960 BERKSHIRE LN
FLOOR 6

(Street)
DALLAS TX 75225

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Pearson Mark E.

(Last) (First) (Middle)
5960 BERKSHIRE LN
FLOOR 6

(Street)
DALLAS TX 75225

(City) (State) (Zip)
Explanation of Responses:
1. Mark Pearson is the Manager and sole Member of Altamont Pharmaceutical Holdings LLC ("Altamont"). Altamont owns 5,280,000 shares of Galera Therapeutics, Inc. Mark Pearson does not personally own any shares. As the Manager and sole Member of Altamont, Mark Pearson possesses the power to vote and dispose of or direct the disposition of 5,280,000 shares.
/s/ Mark Pearson, Manager of Altamont Pharmaceutical Holdings, LLC 04/01/2024
/s/ Mark Pearson 04/01/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.